Covid-19 Qatar vacation Immunization Among Qatari Children and Adolescents

Qatar vacation Dr. Hiam Chemaitelly, Sawsan AlMukdad, M.Sc., Dr. Houssein H. Ayoub, Dr. Heba N. Altarawneh, Dr. Peter Coyle, Dr. Patrick Tang, Dr. Hadi M. Yassine, Dr. Hebah A. Al-Khatib, Dr. Maria K. Smatti, Dr. Mohammad R. Hasan, Dr. Zaina Al-Kana



Qatar vacation Different antigen doses of the BNT162b2 vaccine against coronavirus disease 2019 (Covid-19) have been approved for use in children aged 5 to 11 and teenagers aged 12 to 17.


In Qatar vacation, children and teenagers were tested for their exposure to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in order to determine the real-world efficacy of the BNT162b2 vaccination.

We conducted three matched, retrospective, target-trial cohort studies to compare the incidence of SARS-CoV-2 infection in the national cohort of vaccinated participants with the incidence in the national cohort of unvaccinated participants.

Qatar vacation One study examined data from children aged 5 to 11 years after the B.1.1.529 (omicron) variant became common, and the other two examined face mask in qatar data from adolescents aged 12 to 17 years prior to the emergence of the omicron variant (pre-o). With the use of Cox proportional-hazards regression models, associations were calculated.

RESULTS The 10-g main vaccination series’ overall efficacy in preventing infection with the omicron variant in children was 25.7% (95% confidence interval [CI], 10.0 to 38.6). Qatar vacation Right after receiving the second dosage, effectiveness peaked (49.6%; 95% CI, 28.5 to 64.5) before rapidly waning and becoming inconsequential after three months. The effectiveness was 46.3% (95% CI, 21.5 to 63.3) for kids aged 5 to 7 and 16.6% (95% CI, 4.2 to 33.2) for kids aged 8 to 11.

Qatar vacation The 30-g main vaccine series’ overall efficiency in protecting adolescents from infection with the omicron variant was 30.6% (95% CI, 26.9 to 34.1), but many of them had already had vaccinations months earlier. Since receiving the second dose, the effectiveness has gradually decreased.

Teenagers aged 12 to 14 had an effectiveness of 35.6% (95% CI, 31.2 to 39.6), while those aged 15 to 17 had an effectiveness of 20.9% (95% CI, 13.8 to 27.4). The 30-g main vaccination series’ overall efficacy against SARS-CoV-2 infection in Qatar vacation adolescents was 87.6% (95% CI, 84.0 to 90.4) in the pre-omicron investigation, and it began to decline quite slowly after the second dose.


Children’s vaccinations were linked to a moderate but deteriorating defence against omicron infection. Adolescent vaccination was linked to a greater, longer-lasting immune response, possibly as a result of the higher antigen dosage. (Funded in part by Weill Cornell Medicine-Qatar.)

Children aged 5 to 11 and teenagers aged 12 to 17 are both eligible to receive the messenger RNA (mRNA) vaccination BNT162b2 (Pfizer-BioNTech) against coronavirus disease 2019 (Covid-19), but at antigen doses of 30 g and 10 g, respectively.

Using these vaccinations, Qatar began widespread Covid-19 vaccination programmes, initially vaccinating teenagers in many phases beginning in February 2021 and download vaccination certificate qatar subsequently children aged 5 to 11 beginning in February 2022.(Section S1 in the Supplementary Appendix, which is accessible with this article’s full text at

We evaluated the two-dose main vaccination series’ efficacy in protecting against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents who received the 10-g dose of BNT162b2 vaccine and the 30-g dose, respectively.

In Qatar, where five SARS-CoV-2 waves have occurred, the assessment was a component of a national study. These waves were dominated sequentially by the index virus3, the B.1.1.7 (alpha) variant, the B.1.351 (beta) variant, the B.1.1.529 (omicron) subvariants BA.1 and BA.2,6, and the omicron subvariants BA.4 and BA.5,7 in addition to a protracted low-incidence phase

As part of this investigation, which was carried out in Qatar, we reviewed data from federated national databases for Covid-19 laboratory testing, immunization, hospitalization, and mortality that were collected through a centralized, national digital-health information platform.

Related Articles

Back to top button